Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Moumi Mondal headshot

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold?

by Moumi Mondal

Reaching a new one-year high, Illumina remains in investors' sight owing to its strong strategic execution and positive growth outlook.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

QIAGEN's TB Testing Business Gets New Exposure at Global Summit

by Zacks Equity Research

QGEN distributes over 125 million QuantiFERON-TB tests across more than 130 countries worldwide, significantly contributing to national TB control strategies.

Zacks Equity Research

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies

by Zacks Equity Research

OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.

Moumi Mondal headshot

Should You Bet on HOLX Stock This Breast Cancer Awareness Month?

by Moumi Mondal

Hologic has kicked off the annual breast cancer awareness month with a new campaign. But how well is the stock doing now?

Zacks Equity Research

Reasons to Retain QIAGEN Stock in Your Portfolio for Now

by Zacks Equity Research

Investors feel optimistic about QGEN's strong growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is cornering.

Zacks Equity Research

QIAGEN Launches QIAcuityDx Digital PCR System: Stock to Gain?

by Zacks Equity Research

QGEN expands its digital PCR portfolio with the newly launched QIAcuityDx Digital PCR System. The system will be used for clinical testing in oncology across North America and Europe.

Zacks Equity Research

QGEN Stock to Gain From New IVDR Win for QIAstat-Dx Systems and Panels

by Zacks Equity Research

QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays.

Zacks Equity Research

QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene

by Zacks Equity Research

PreAnalytiX, a joint venture of QGEN and BD, introduces the PAXgene Urine Liquid Biopsy Set. QGEN will commercialize the latest set.

Zacks Equity Research

QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO

by Zacks Equity Research

QIAGEN announces exclusive global commercial partnership with Bode Technology. Per the agreement, Bode will manage all commercial transactions for QIAGEN's GEDmatch PRO globally.